Based on moderate quality evidence , due to concerns about risk of bias and imprecision , initiation of statin therapy within 14 days following ACS does not reduce death , myocardial infa rct ion , or stroke up to four months , but reduces the occurrence of unstable angina at four months following ACS .
Serious side effects were rare
BACKGROUND The early period following the onset of acute coronary syndrome ( ACS ) represents a critical stage of coronary heart disease , with a high risk of recurrent events and deaths .
The short-term effects of early treatment with statins on patient-relevant outcomes in patients suffering from ACS are unclear .
This is an up date of a review previously published in 2011 .
OBJECTIVES To assess the effects , both harms and benefits , of early administered statins in patients with ACS , in terms of mortality and cardiovascular events .
Effects of short-term anti-inflammatory therapy on endothelial function in patients with non-ST-segment elevation acute coronary syndrome.
The aim was to assess the impact of the short-term anti-inflammatory therapy on coronary endothelial function in non-ST-segment elevation acute coronary syndrome patients . In 30 patients , coronary endothelial function was assessed by acetylcholine test . Vessel response was calculated as a percent change of mean lumen diameter ( MLD ) . Then patients were r and omized into three groups : A ( n = 11 ) placebo , B ( n = 11 ) 80 mg atorvastatin , C ( n = 8) 80 mg atorvastatin and 25 mg rofecoxib . After 7 days control test was performed . Recovery of coronary endothelial function was calculated as delta in percent changes of MLD between Days 1 and 7 . On Day 1 , percent change of MLD between baseline and maximum acetylcholine did not differentiate the groups : -20 ± 3.5 % in A , -25 ± 3.9 % in B and -26 ± 3.7 % in C , P = .20 . On Day 7 , percentage changes in MLD were as follows : -21 ± 3.9 % in A , -15 ± 3.0 % in B and -10 ± 4.0 % in C , P=.002 . The delta in percentage change in MLD between Days 1 and 7 were as follows : -1 % in A , + 10 % in B and + 16 % in C , P = .02 . In conclusion , short-term , anti-inflammatory therapy with high-dose atorvastatin and selective cyclooxygenase-2 inhibitor improves coronary endothelial function within 7 days in non-ST-segment elevation acute coronary syndrome patients
Based on moderate quality evidence , due to concerns about risk of bias and imprecision , initiation of statin therapy within 14 days following ACS does not reduce death , myocardial infa rct ion , or stroke up to four months , but reduces the occurrence of unstable angina at four months following ACS .
Serious side effects were rare
BACKGROUND The early period following the onset of acute coronary syndrome ( ACS ) represents a critical stage of coronary heart disease , with a high risk of recurrent events and deaths .
The short-term effects of early treatment with statins on patient-relevant outcomes in patients suffering from ACS are unclear .
This is an up date of a review previously published in 2011 .
OBJECTIVES To assess the effects , both harms and benefits , of early administered statins in patients with ACS , in terms of mortality and cardiovascular events .